005250

GC Corp. is a holding company that manages a group of biotechnology and healthcare companies. Its primary subsidiary, GC Biopharma, manufactures and sells blood-derived products, vaccines, and specialty pharmaceuticals, including immunoglobulins, albumin, and treatments for rare diseases such as Hunter syndrome. The group also operates GC Cell, which develops cell therapy products and provides contract development and manufacturing services, and GC Medical Foundation, which offers clinical laboratory testing services. The company serves hospitals, clinics, pharmacies, and public health organizations in South Korea and international markets, including the United States, China, and Europe. Key products include ALYGLO, Barycela, Hunterase, and GreenGene F. The group also engages in digital healthcare, consumer health products, and cold-chain logistics through its subsidiaries.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage gccorp.com
Sector Healthcare IR page gccorp.com/kor/ir/ir
Tags
blood products, vaccines, rare disease therapeutics, cell therapy, clinical diagnostics, cold-chain logistics, consumer health, digital healthcare, cdmo services, cord blood banking, GC Biopharma, GC Cell, GC Medical Foundation, ALYGLO, Barycela, Hunterase, GreenGene F, Curevo Inc., Able2Care, GC Biopharma MS, GC Care, GC Wellness, GC Medai, GCL, G-HUB, Immuncell-LC, GCC2005, GC1123B, GC1130A, GC1134A, GC4006A, GC3111B, MG1111D, GC3107A, Hepabig, EUGAMMA, GCFLU, Vaxirax, Glabzia, Livmarli, Nokxaban, GCC5694A
Press page gccorp.com/kor/pr/news

Metrics

Valuation  
Market cap ₩ 494.44B
Market cap (USD) $ 363.899M
P/E -3.63
PEG —
P/BV 0.57
P/S 0.20
P/OCF 3.01
P/FCF 13.34
Dividend yield —
Turnover / mcap —
Returns  
ROE -7.3%
ROI -7.7%
ROIC 3.0%
Profit margin -2.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 2.451T 2.205T 2.058T 2.08T 1.841T 1.719T 1.525T 1.549T 1.465T 1.354T 1.133T 1.045T 938.298B
Net profit -69.513B 24.025B -54.136B 32.823B 55.27B 170.96B 2.957B 18.467B 43.364B 47.177B 65.421B 56.761B 43.55B
Free cash flow -86.57B -133.812B -129.579B 23.947B -10.328B -70.303B -131.278B -80.354B -30.45B -160.664B -144.786B -23.712B -82.013B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 16.53K — — — — — — — — — — — —
P/FCF -9.46 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 363B 391B 398B 411B 461B 466B 475B 537B 452B —
↳ YoY growth +23.6% +7.6% +2.0% +3.2% +12.0% +1.1% +1.9% +13.2% -15.8%
↳ 5y CAGR +9.5% +10.5% +9.4% +5.1% +4.0% +6.2% +1.9%
Other receivables (KRW) — — — — — — 32B 30.4B 32.9B 30B
Borrowings, current (KRW) — — — — — — 603B 1.01T 679B 381B
Borrowings, non-current (KRW) 251B — — — — — 448B 216B 411B 476B
Lease liabilities (KRW) — — — 4.48B 3.49B 6.35B 11.7B 16.2B 36.3B 126B
Cash and deposits (KRW) 114B 269B 251B 176B 448B 336B 209B 175B 77.3B 79.7B
Intangible assets (KRW) 80.9B 113B 133B 140B 314B 533B 666B 694B 664B 724B
Right-of-use assets (KRW) — — — 39.8B 18.7B 20.5B 39.2B 50.1B 28.8B 86.1B
Net debt (borrowings + leases - cash) (KRW) 137B — — — — — 889B 1.11T 1.05T 902B
Cash flow detail
Operating cash flow (KRW) -805M 144B 37.6B 7.65B 38.1B 104B 97.2B -39.7B -89.9B 24.3B
Purchases of property, plant and equipment (KRW) -160B -175B -118B -139B -108B -114B -73.2B -89.9B -43.9B -111B
Purchases of intangible assets (KRW) -19.6B -36.2B -30B -26.1B -27.3B -27.7B -54B -42.7B -13.9B -39.2B
Dividends paid (cash effect) (KRW) -23.9B -22.1B -22.1B -18.3B -21.5B -32.2B -31.5B -29.9B -25.4B -33.2B
Share buybacks (cash effect) (KRW) — -538M — — — — — — — —
Interest paid (cash effect) (KRW) -10.9B -13.2B -17.1B -16.7B -28.7B -28.8B -34.2B -47.5B -66.6B -71.4B
Income taxes paid (cash effect) (KRW) -49.5B -34.3B -36.1B -32B -17.8B -35.4B -56.5B -23.5B -5.26B -58.8B
Free cash flow (OCF - PPE - intangibles) (KRW) -180B -66.6B -110B -157B -97.6B -38.1B -30B -172B -148B -126B
Income detail
Total comprehensive income (KRW) 78.5B 83.9B -5.08B -28.3B 185B 155B 80.6B -59.8B -23.2B -53.3B
Comprehensive income to owners (KRW) 48.4B 55.4B -49.8M 2.66B 172B 78.1B 45.9B -48.9B 17.3B -77.2B
Reported Mar 31, 2017 Apr 2, 2018 Apr 1, 2019 May 22, 2020 Mar 17, 2021 Mar 20, 2024 Mar 18, 2025 Mar 18, 2025 Mar 18, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Results
최대주주등소유주식변동신고서 Bull 0 Bear 0 Routine

Prompts

GC Corp. (ticker 005250), listed in South Korea.

ETFs Holding GC Corp.

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 2,557 $ 17.816K Nov 16, 2026
DFEV 0.00% 12,642 $ 92.36K Nov 12, 2026
DFEM 0.00% 31,998 $ 233.771K Nov 12, 2026
DFSE 0.00% 1,601 $ 11.697K Nov 12, 2026
DFAX 0.00% 18,641 $ 136.187K Nov 12, 2026
DFAE 0.00% 12,834 $ 93.763K Nov 12, 2026
AVEM 0.00% 2,440 $ 17.001K Nov 16, 2026
AVXC 0.00% 27 $ 188.12 Nov 16, 2026